BDBM384356 US10590114, No. 39A::US11111235, No. 39A::US11591316, Compound 39A::US9932325, Example 39A
SMILES Cc1nn(cc1Nc1ncc(c(N[C@H]2C[C@H]2F)n1)C(F)(F)F)C(C)(C)C#N
InChI Key InChIKey=ITORPRYAIDITDX-UHFFFAOYSA-N
Data 4 IC50
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 4 hits for monomerid = 384356
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: 30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well assay plate DMSOEnzyme Reaction Condition...More data for this Ligand-Target Pair
Affinity DataIC50: 30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well assay plate DMSOEnzyme Reaction Condition...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: 30nMAssay Description:Materials:LRRK2 G2019S enzymeSubstrate (LRRKtide)ATPTR-FRET dilution bufferpLRRKtide antibody384-well assay plateDMSOEnzyme Reaction Conditions50 mM ...More data for this Ligand-Target Pair
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Human)
Denali Therapeutics
US Patent
Denali Therapeutics
US Patent
Affinity DataIC50: 30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
